Transoma brings in $5M for heart diagnostics
Transoma, maker of cardiovascular monitoring and diagnostic products, landed $5 million in fourth-round funding from United Therapeutics, Affinity Capital Management, Canaan Partners, Cross Creek Capital and Polaris Venture Partners, reports VentureWire. The money comes after the company withdrew its filing to go public earlier this year.
Based in St. Paul, Minn., the biotech company hoped to bring in $67.2 million on 4.2 million shares, but decided against going public due to unfavorable market conditions. Before it filed in November, it had raised $37 million in VC backing.
Next Story: PlantSense launches EasyBloom plant monitoring sensors
Previous Story: Xanodyne newest pharm co. to cancel IPO
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.